United-Guardian, Inc. (UG) Forms $18.10 Double Top; 8 Analysts Bullish GlaxoSmithKline plc (GSK)

Among 18 analysts covering GlaxoSmithKline (NYSE:GSK), 8 have Buy rating, 1 Sell and 9 Hold. Therefore 44% are positive. GlaxoSmithKline had 27 analyst reports since September 8, 2015 according to SRatingsIntel. The rating was downgraded by Bank of America on Thursday, October 26 to “Hold”. Bryan Garnier & Cie upgraded the shares of GSK in report on Wednesday, January 27 to “Buy” rating. The stock has “Neutral” rating by Citigroup on Wednesday, July 5. The rating was maintained by J P Morgan Chase Co on Friday, June 16 with “Neutral”. Credit Suisse upgraded the stock to “Neutral” rating in Tuesday, October 20 report. The stock has “Neutral” rating by BNP Paribas on Tuesday, September 15. The firm has “Neutral” rating by JP Morgan given on Monday, October 12. The firm has “Hold” rating by Cowen & Co given on Monday, December 11. The company was initiated on Friday, September 23 by Piperjaffray. On Wednesday, September 14 the stock rating was downgraded by BNP Paribas to “Underperform”. See GlaxoSmithKline plc (NYSE:GSK) latest ratings:

16/01/2018 Broker: Barclays Capital Rating: Buy Upgrade
11/12/2017 Broker: Cowen & Co Rating: Hold New Target: $38.0 Maintain
30/11/2017 Broker: Argus Research Rating: Buy New Target: $40.0
27/11/2017 Broker: UBS Rating: Buy Upgrade
26/10/2017 Broker: Bank of America Rating: Hold Downgrade
08/09/2017 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Underweight Downgrade

United-Guardian, Inc. (UG) formed double top with $19.73 target or 9.00% above today’s $18.10 share price. United-Guardian, Inc. (UG) has $83.16 million valuation. The stock decreased 2.52% or $0.47 during the last trading session, reaching $18.1. About 2,220 shares traded. United-Guardian, Inc. (NASDAQ:UG) has declined 10.72% since February 6, 2017 and is downtrending. It has underperformed by 27.42% the S&P500.

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company has market cap of $78.98 billion. It operates through four divisions: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. It has a 26.6 P/E ratio. The firm offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV.

The stock decreased 4.34% or $1.61 during the last trading session, reaching $35.49. About 6.25M shares traded or 25.28% up from the average. GlaxoSmithKline plc (NYSE:GSK) has risen 4.26% since February 6, 2017 and is uptrending. It has underperformed by 12.44% the S&P500.

Investors sentiment increased to 1.83 in Q3 2017. Its up 1.05, from 0.78 in 2017Q2. It increased, as 2 investors sold United-Guardian, Inc. shares while 4 reduced holdings. 4 funds opened positions while 7 raised stakes. 1.07 million shares or 3.61% more from 1.03 million shares in 2017Q2 were reported. Parthenon Ltd has 0.51% invested in United-Guardian, Inc. (NASDAQ:UG). Utd Capital Fin Advisers Ltd accumulated 66,550 shares. Bridgeway Mgmt Inc stated it has 10,000 shares or 0% of all its holdings. The New York-based Gamco Incorporated Et Al has invested 0.02% in United-Guardian, Inc. (NASDAQ:UG). Blackrock reported 21,857 shares. Dimensional Fund Advsr L P invested in 0% or 115,686 shares. Deutsche Savings Bank Ag accumulated 7,466 shares. Acadian Asset Lc, Massachusetts-based fund reported 460 shares. Teton Inc stated it has 77,900 shares. Clearbridge Invs Limited Liability Corp has 2,000 shares for 0% of their portfolio. Royal Comml Bank Of Canada, a Ontario – Canada-based fund reported 100 shares. Renaissance Techs Lc stated it has 0% of its portfolio in United-Guardian, Inc. (NASDAQ:UG). Eagle Ridge Invest Management has invested 0.05% in United-Guardian, Inc. (NASDAQ:UG). Frontier Invest Mngmt holds 11,000 shares. Northern Trust Corp accumulated 10,763 shares or 0% of the stock.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: